Ipsen S.A. (IPSEF)

OTCMKTS · Delayed Price · Currency is USD
125.37
0.00 (0.00%)
At close: Oct 22, 2024
6.53%
Market Cap 9.39B
Revenue (ttm) 3.68B
Net Income (ttm) 729.88M
Shares Out n/a
EPS (ttm) 8.73
PE Ratio 12.87
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 163
Open 125.37
Previous Close n/a
Day's Range 125.37 - 125.37
52-Week Range 108.75 - 132.50
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 13, 2025

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]

Sector Healthcare
Founded 1929
Employees 5,325
Stock Exchange OTCMKTS
Ticker Symbol IPSEF
Full Company Profile

Financial Performance

In 2023, Ipsen's revenue was 3.31 billion, an increase of 4.75% compared to the previous year's 3.16 billion. Earnings were 644.40 million, a decrease of -0.65%.

Financial numbers in EUR Financial Statements

News

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's long-term prospects remain uncertain.

12 days ago - Seeking Alpha

Ipsen S.A. reports Q3 results; raises FY24 guidance

Ipsen S.A. press release (IPSEY): Q3 Revenue of €836.6M (+8.3% Y/Y). Full-year 2024 guidance: Based on the strong performance in the third quarter, Ipsen has further increased

5 weeks ago - Seeking Alpha

Eton Pharmaceuticals to buy Increlex product from Ipsen

Expert financial writer providing valuable insights on investment strategies, market trends, and personal finance tips for readers.

2 months ago - Seeking Alpha

Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

Kayfanda ® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda...

2 months ago - Benzinga

Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows pos...

2 months ago - Benzinga

Employee of French drugmaker Ipsen to plead guilty to US insider trading

An employee of French drugmaker Ipsen has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug dev...

3 months ago - Reuters

Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report

4 months ago - GlobeNewsWire

Annual General Meeting of Ipsen S.A. held on 28 May 2024

PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France...

6 months ago - GlobeNewsWire

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024

PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of t...

6 months ago - GlobeNewsWire

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BIL...

7 months ago - GlobeNewsWire

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.

7 months ago - GlobeNewsWire

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

8 months ago - Seeking Alpha

2 More Potential Biotech Buyout Targets

M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ...

9 months ago - Seeking Alpha

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements

10 months ago - GlobeNewsWire

US FDA approves Ipsen's rare bone disorder drug

The U.S. Food and Drug Administration on Wednesday approved French drugmaker Ipsen's bone disorder drug, making it the first treatment available to patients with the rare condition that causes abnorma...

1 year ago - Reuters

US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated fo...

1 year ago - GlobeNewsWire

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Ipsen S.A. publishes its 2023 Half-Year Financial Report Attachment 2023 Half-year Financial Report

1 year ago - GlobeNewsWire

Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan

REGULATED INFORMATION Ipsen initiates a share buy-back program to cover its free employee share-allocation plan Paris (France), 1 June 202 3 - Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an invest...

1 year ago - GlobeNewsWire

Ipsen S.A. - Combined Shareholders' Meeting of Ipsen S.A. held on 31 May 2023

REGULATED INFORMATION  COMBINED SHAREHOLDERS' MEETING OF IPSEN S.A. HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS' VOTE HAVE BEEN APPROVED Paris (France), 31 May 2023 – The Com...

1 year ago - GlobeNewsWire

Ipsen delivers a strong sales performance in the first quarter of 2022

Ipsen delivers a strong sales performance in the first quarter of 2022 Paris (France), 27 April 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes i...

1 year ago - GlobeNewsWire

Ipsen S.A. publishes its 2022 Universal registration document

Paris (France), 6 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, announced today that its 2022 Universal Registration Document has been filed with t...

1 year ago - GlobeNewsWire

Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript

Ipsen S.A. (OTCPK:IPSEY) Q4 2022 Results Conference Call February 9, 2023 7:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conf...

1 year ago - Seeking Alpha

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

Investigational Onivyde® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compar...

2 years ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "...

2 years ago - PRNewsWire

Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) announced the Ipsen (Euronext: IPN; ADR: IPSEY) anno...

2 years ago - Business Wire